Atlas Trials

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Clinical trial NCT02983604 · TERMINATED

Trial details

NCT number
NCT02983604
Sponsor
Gilead Sciences
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Start date
2017-01-10
Primary completion
2018-07-19
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.